Stock Screener App

무료 -

Drug Manufacturers - Specialty & Generic

16.16

1.48% +0.235

시간 외 거래: 15.83 -0.33 -2.04%

Harrow Inc (HROW)

개요 뉴스 가격 이력 옵션 체인 Financials HROW 왜 하락? 토론 예측 주식 분할

Harrow Inc 주식(HROW)의 최신 뉴스

B. Riley Research Analysts Lower Earnings Estimates for Harrow, Inc. (NASDAQ:HROW) - MarketBeat

Harrow Inc [HROW] stock for 199400 USD was bought by Opaleye Management Inc. – Knox Daily - Knox Daily

Craig Hallum Increases Harrow (NASDAQ:HROW) Price Target to $26.00 - MarketBeat

Harrow (NASDAQ:HROW) Rating Reiterated by B. Riley - MarketBeat

Harrow, Inc. (NASDAQ:HROW) to Post Q4 2024 Earnings of $0.17 Per Share, B. Riley Forecasts - MarketBeat

The growth track for Harrow Inc (HROW) has changed recently – Sete News - SETE News

Harrow to Present at Two Investor Conferences in May - Business Wire

Earnings call: Harrow Inc. reports robust revenue growth in Q1 2024 - Investing.com

Harrow (NASDAQ:HROW) Shares Gap Up to $12.07 - MarketBeat

Harrow Market 2023-2030 Insight View with Size and Regional Analysis | Survey Report by Absolute Reports - NEWS CHANNEL NEBRASKA

NEWS CHANNEL NEBRASKA

Examining Harrow Inc (HROW) stock is warranted – US Post News - US Post News

Harrow: Q1 Earnings Snapshot | Tennessee News - Crossville Chronicle

Crossville Chronicle

Harrow Announces First Quarter 2024 Financial Results - Yahoo Finance

Harrow Names Greg DiPasquale as Senior Vice President, Head of Commercial - Business Wire

Harrow: Q1 Earnings Snapshot - Houston Chronicle

Houston Chronicle

Harrow Borough FC part company with manager and three coaches - Harrow Online

VYNE Therapeutics Inc. (VYNE) Reports Q1 Loss, Misses Revenue Estimates

Zacks Investment Research

EyePoint Pharmaceuticals and Harrow Health’s ImprimisRx Announce Expanded U.S. Commercial Alliance for ... - The Globe and Mail

The Globe and Mail

Harrow (HROW) is on the Move, Here's Why the Trend Could be Sustainable - Yahoo Movies Canada

Yahoo Movies Canada

Harrow: The Bull Thesis Is On Track, But Short-Term Challenges Loom (NASDAQ:HROW) - Seeking Alpha

Around $2M Bet On This Industrial Stock? Check Out These 3 Stocks Insiders Are Buying - Harrow (NASDAQ:HR - Benzinga

Opaleye management buys $204k of Harrow Inc. stock - Investing.com

Insider Buying: Harrow, Inc. (NASDAQ:HROW) Major Shareholder Buys 11,715 Shares of Stock - MarketBeat

Over $24M Bet On RXO? Check Out These 3 Stocks Insiders Are Buying - Harrow (NASDAQ:HROW), RXO (NYSE:RXO) - Benzinga

Drug company defends 486% price increase for eye treatment - STAT

Melt Pharmaceuticals raises $24 million for drug development - Nashville Business Journal - The Business Journals

The Business Journals

Opaleye Management Inc. buys $641k of Harrow Inc. common stock - Investing.com

Insiders Buying Greenwich LifeSciences And 2 Other Stocks

Insiders Buying Greenwich LifeSciences And 2 Other Stocks - Markets Insider

Markets Insider

Why Taysha Gene Therapies Shares Are Trading Higher By Around 27%; Here Are 20 Stocks Moving Premarket

Harrow Posts Weak Q4 Results, Joins TeraWulf, Nasdaq And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Why Is Harrow (HROW) Stock Down 7% Today? - InvestorPlace

Harrow Inc (HROW) Reports Substantial Revenue Growth Amidst Net Loss Expansion in 2023 - GuruFocus.com

Harrow: Q4 Earnings Snapshot - Quartz

Disgraced Harrow company director convicted of falsifying medicine quality data - Harrow Online

Harrow Health (HROW) Set to Announce Earnings on Tuesday - American Banking and Market News

American Banking and Market News

Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results After Market Close on March 19, 2024 - Business Wire

Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products - Vision Monday

Harrow's Drug Iheezo Is Off To A Great Start (NASDAQ:HROW) - Seeking Alpha

Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products - Business Wire

Harrow Announces New Appointments to Board of Directors - Vision Monday

Harrow Announces New Appointments to its Board of Directors - Business Wire

Harrow Announces Availability of VEVYE® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine ... - Business Wire

Vevye Partners with PhilRx, Apollo Care, and PARx Solutions to Enhance Patient Access to Innovative Dry Eye Treatment - Medriva

Melt Pharmaceuticals Provides Corporate Update - Yahoo Finance

Harrow Completes Transfer of the TRIESENCE® New Drug Application - Yahoo Finance

Harrow to Present at Two Investor Conferences in November - Business Wire

Opaleye Management Inc. Bolsters Position in Harrow Inc. with Recent Acquisition - Yahoo Finance

Despite Q3 Earnings Miss, Harrow Is Still Appealing For 2024 (NASDAQ:HROW) - Seeking Alpha

HROW Stock Quote Price and Forecast - CNN

$66.53

0.46%

$16.98

0.35%

$55.25

0.65%

$69.30

0.50%

$11.02

0.45%

$141.91

0.06%

야후에서 열기 | 구글에서 열기 | 핀비즈에서 열기